Announced details
Lower rectal cancer and anal cancer. Patients eligible for preoperative chemoradiotherapy.
Recipient of the clinical trial notification for OBP-301. Capital, personnel, and business relationships are Not disclosed.
Pharmaceuticals and Medical Devices Agency. Other information on its location, representative, business activities, capital, and year of establishment is Not disclosed.
The impact on financial results for the fiscal year ending December 2026 is expected to be immaterial. Following approval as a regenerative medical product with esophageal cancer as the initial indication and inclusion in the NHI drug price list, the company plans to begin sales of OBP-301 during the fiscal year ending December 2026 as scheduled.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Oncolytic virus OBP-301 |
| Counterparty | Pharmaceuticals and Medical Devices Agency (PMDA), an independent administrative agency |
| Counterparty overview | Pharmaceuticals and Medical Devices Agency. Other information on its location, representative, business activities, capital, and year of establishment is Not disclosed. |
| Relationship with the Company | Recipient of the clinical trial notification for OBP-301. Capital, personnel, and business relationships are Not disclosed. |
| Launch date | Dosing in the trial is planned to begin during the fiscal year ending December 2026. |
| Applicable area | Lower rectal cancer and anal cancer. Patients eligible for preoperative chemoradiotherapy. |
| Impact on Business Performance | The impact on financial results for the fiscal year ending December 2026 is expected to be immaterial. Following approval as a regenerative medical product with esophageal cancer as the initial indication and inclusion in the NHI drug price list, the company plans to begin sales of OBP-301 during the fiscal year ending December 2026 as scheduled. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The trial will evaluate the efficacy and safety of combining preoperative chemoradiotherapy with OBP-301. In addition, because the decline in quality of life resulting from colostomy associated with resection is well known, the company decided to develop OBP-301 in this new indication under the development concept of treating cancer without surgery.